In the corridors of the pharmaceutical industry, where breakthroughs are celebrated and lives are changed, there’s a quieter, yet critical, conversation underway – one centred on diversity and inclusivity.
The Association of the British Pharmaceutical Industry (ABPI) has recently offered insights into this dialogue through its ED&I strategy. Within its pages lie revelations about the industry’s strides and stumbles in embracing equality, diversity and inclusion (ED&I).
One thing that jumps out from the ABPI report is the growing sense of accountability among pharmaceutical companies.
Check out the rest of the feature here
